Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice

Therapeutic Advances in Urology

Volumn 6, Issue 1, 2014, Pages 34-42

  Knuepfer, Stephanie ^a   Juenemann, Klaus Peter ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

botulinum toxin injection; neurogenic bladder dysfunction; overactive bladder; urinary bladder

Indexed keywords

BOTULINUM TOXIN A;

CLINICAL PRACTICE; HEALTH CARE SYSTEM; HUMAN; LOWER URINARY TRACT SYMPTOM; OVERACTIVE BLADDER; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; URINE INCONTINENCE;

EID: 84892645081     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213510962     Document Type: Review

References (46)

1. Abdel-Meguid T. (2010) Botulinum toxin A injections into neurogenic overactive bladder- to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184: 2423–2428.
2. Abrams P. Cardozo L. Fall M. Griffiths D. Rosier P. Ulmsten U. (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167.
3. Apostolidis A. Dasgupta P. Denys P. Elneil S. Fowler C. Giannantoni A. (2009a) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55: 100–119.
4. Cruz F. Herschorn S. Alicotta P. Brin M. Thompson C. Lam W. (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur J Urol 60: 742–750.
5. Datta S. Roosen A. Pullen A. Popat R. Rosenbaum TP. Elneil S. (2010) Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 184: 2578–2585.
6. deGroat W. (1997) A neurologic basis for the overactive bladder. Urology 50(S6A): 36.
7. De Laet K. Wyndaele J. (2005) Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43: 397–399.
8. de Paiva A. Meunier F. Molgo J. Aoki KR. Dolly JO. (1999) Functional repair of motor endplates after botulinum neurotoxin type A poising: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96: 3200–3205.
9. Drake M. Mills I. Gillespie J. (2001) Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 358: 437.
10. Fowler C. Griffiths D. de Groat W. (2008) The neural control of micturition. Nat Rev Neurosci 2008; 9: 453–466.
11. Game X. Castel-Lacanal E. Bentaleb Y. Thiry-Escudié I. De Boissezon X. Malavaud B. (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infection. Eur J Urol 53: 613–618.
12. Game X. Khan S. Panicker J. Kalsi V. Dalton C. Elneil S. (2010) Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. Br J Urol 107: 1786.
13. Game X. Mouracade P. Chartier-Kastler E. Viehweger E. Moog R. Amarenco G. Denys P. (2009) Botulinum toxin A intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. J Ped Urol 5: 156–164.
14. Gill D. (1982) Bacterial toxins: A table of lethal amounts. Microbiol Rev 46: 86–94.
15. Gillespie J. van Koeveringe G. de Wachter S. de Vente J. (2009) On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 103: 1324.
16. Ginsberg D. Gousse A. Keppenne V. Sievert KD. Thompson C. Lam W. (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187: 2131–2139.
17. Grosse J. Kramer G. Stohrer M. (2005) Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur J Urol 2005; 47: 653–659
18. Herschorn S. Gajewski J. Ethans K. Carlson K. Bailly G. Bard R. (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 185: 2229–2235.
19. Karram M. (1999) Detrusor instability and hyperreflexia. In: Walters M. Karram M. (eds), Clinical Urogynecology, 2nd edn. St. Louis, MO: Mosby.
20. Karsenty G. Denys P. Amarenco G. De Seze M. Gamé X. Haab F. (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53: 275–287.
21. Kennelly M. Dmochowski R. Ethans K. Karsenty G. Schulte-Baukloh H. Jenkins B. (2012) Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. J Urol 81: 491–497.
22. Kessler T. Danuser H. Schumacher M. Studer UE. Burkhard FC. (2005) Botulinum A Toxin injection into detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodynam 24: 231–236.
23. Khera M. Somogyi G. Kiss S. Boone TB. Smith CP. (2004) Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45: 987–993.
24. Kruse M. Mallory B. Noto H. Roppolo JR. de Groat WC. (1991) Properties of the descending limb of the spinobulbospinal micturition reflex pathway in the cat. Brain Res 556: 6–12.
25. Kuo H. (2006) Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68: 993–997.
26. Lucioni A. Rapp D. Gong E. Fedunok P. Bales GT. (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 13: 3291–3295.
27. Mangera A. Andersson K. Apostolidis A. Chapple C. Dasgupta P. Giannantoni A. (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol. 4: 784–795.
28. Mehnert U. Boy S. Schmid M. Reitz A. von Hessling A. Hodler J. (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27: 397–403.
29. Montecucco C. Schiavo G. (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28: 423–472.
30. Pannek J. Goecking K. Bersch U. (2009) Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. Br J Urol 104: 1246–1250.
31. Rackley R. Frenkl T. Abdelmalak J. (2005) Botulinum toxin: the promise of therapy for complex voiding dysfunction. Cont Urol 2: 38–52.
32. Rapp D. Lucioni A. Bales G. (2007) Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol 33: 132–141.
33. Reitz A. Denys P. Fermanian C. Schurcb B. Comperat E. Chartier-Kastler E. (2007) Do repeated intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur J Urol 5: 1729–1735.
34. Reitz A. Schurch B. (2004) Intravesical therapy options for neurogenic overactivity. Spinal Cord 42: 267–272.
35. Schiavo G. Santucci A. Dasgupta B. Mehtad P. Jontesd J Benfenati F. (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335: 99–103.
36. Schulte-Baukloh H. Michael T. Schobert J. Stolze T. Knipsel HH. (2002) Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. J Urol 59: 325–327.
37. Schulte-Baukloh H. Michael T. Stürzebecher B. Knispel HH. (2003) Botulinum A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44: 139–143.
38. Schurch B. Denys P. Kozma Kozma CM. Reese PR. Slaton T. Barron R. (2007) Botulinum toxin A improves quality of life of patients with neurogenic urinary incontinence. Eur Urol 52: 850–859.
39. Schurch B. de Seze M. Denys P. Chartier-Kastler E. Haab F. Everaert K. (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: result of a single treatment randomized, placebo controlled 6-month study. J Urol 174: 196–200.
40. Schurch B. Schmid D. Stohrer M. (2000a) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342: 665.
41. Schurch B. Stohrer M. Kramer G. Schmid D. Gaul G. Hauri D. (2000b) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692–697.
42. Shaban A. Drake M. (2008) Botulinum toxin treatment for overactive bladder: risk of urinary retention. Curr Urol Rep 9: 445–451.
43. Smith C. Boone T. de Groat W. Chancellor MB. Somogyi GT. (2003a) Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 61: 165–171.
44. Smith C. Franks M. McNeil B. Ghosh R. de Groat WC. Chancellor MB. (2003b) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169: 1896–1900.
45. Smith C. Nishiguchi J. O–Leary M Yoshimura N Chancellor MB. (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. J Urol 65: 37–41.
46. Yokoyama T. Chancellor MB. Oguma K. Yamamoto Y. Suzuki T. Kumon H. (2012) Botulinum toxin type A for treatment of lower urinary tract disorders. J Urol 19: 202–215.